MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
36.52
+3.23
+9.70%
After Hours: 36.52 0 0.00% 16:56 06/21 EDT
OPEN
33.48
PREV CLOSE
33.29
HIGH
36.54
LOW
33.48
VOLUME
3.75M
TURNOVER
0
52 WEEK HIGH
44.66
52 WEEK LOW
17.53
MARKET CAP
2.80B
P/E (TTM)
-4.7516
1D
5D
1M
3M
1Y
5Y
PTC THERAPEUTICS INC <PTCT.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $37 FROM $28
Reuters · 13h ago
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
Shares of Asana, Inc. Jumped 13.4% to $12.90 on Friday. Asana announced a $150 million share repurchase program and reaffirmed its forward guidance. Sarepta Therapeutics shares jumped 39.2% after FDA approval of expanded indication for Duchenne muscular dystrophy.
Benzinga · 14h ago
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), PTC Therapeutics (PTCT) and Alnylam Pharma (ALNY)
TipRanks · 16h ago
PTC Therapeutics Price Target Raised to $32.00/Share From $25.00 by B of A Securities
Dow Jones · 18h ago
PTC Therapeutics Is Maintained at Underperform by B of A Securities
Dow Jones · 18h ago
B of A Securities Maintains Underperform on PTC Therapeutics, Raises Price Target to $32
Benzinga · 18h ago
PTC THERAPEUTICS INC <PTCT.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $32 FROM $25
Reuters · 18h ago
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Silence Therapeutics (SLN) and PTC Therapeutics (PTCT)
TipRanks · 19h ago
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.